Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Factors associated with successful TFR in patients with CML who have discontinued TKI therapy

Fadi Haddad • 24 Jun 2022
EHA 2022
Chronic Myeloid Leukemia Leukemia Dasatinib Imatinib Nilotinib

Fadi Haddad, MD, MD Anderson Cancer Center, Houston, TX, comments on the results of a study investigating the factors associated with a successful treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) who have discontinued treatment with imatinib, dasatinib, and nilotinib. The study revealed that a deep molecular response rate of four (MR4) or MR4.5 for five years or longer is the most important indicator for successful TFR. In addition, the study showed that the type of frontline TKI or the reason for treatment discontinuation did not impact TFR. Lastly, the study reported that patients who relapsed after treatment discontinuation were able to regain a deep molecular response. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Fadi Haddad

2:32
Blinatumomab and ponatinib in newly diagnosed Ph+ ALL: updates from a Phase II trial
Fadi Haddad • 11 Dec 2023
4:49
Dasatinib plus venetoclax in ECP-CML: insights from a Phase II study
Fadi Haddad • 11 Dec 2023
8:36
FLT3 mutational status can change between diagnosis and relapse in patients with AML
Fadi Haddad • 23 Nov 2022
2:51
The emergence of novel antibodies, CAR-T and CAR-NK therapies in AML
Fadi Haddad • 23 Nov 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals